​

Regeneron Pharmaceuticals (REGN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

REGN Stock Forecast

Regeneron Pharmaceuticals stock forecast is as follows: an average price target of $1.14K (represents a 61.74% upside from REGN’s last price of $701.85) and a rating consensus of 'Buy', based on 26 wall street analysts offering a 1-year stock forecast.

REGN Price Target

The average price target for Regeneron Pharmaceuticals (REGN) is $1.14K based on 1-year price targets from 26 Wall Street analysts in the past 3 months, with a price target range of $1.29K to $805.00. This represents a potential 61.74% upside from REGN's last price of $701.85.

REGN Analyst Ratings

Buy

According to 26 Wall Street analysts, Regeneron Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for REGN stock is 0 'Strong Buy' (0.00%), 22 'Buy' (84.62%), 4 'Hold' (15.38%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Regeneron Pharmaceuticals Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 01, 2024Evan David SeigermanBMO Capital$1.19K$843.6041.06%69.55%
Nov 01, 2024Christopher RaymondPiper Sandler$1.20K$843.6041.65%70.26%
Nov 01, 2024Andrew BerensLeerink Partners$880.00$843.604.31%25.38%
Oct 31, 2024Cory KasimovEvercore ISI$1.17K$838.2039.58%66.70%
Oct 24, 2024Cory KasimovEvercore ISI$1.18K$941.3924.82%67.41%
Oct 23, 2024Mohit BansalWells Fargo$1.05K$962.349.11%49.60%
Sep 24, 2024Thomas KleeTruist Financial$1.20K$1.09K9.89%70.98%
Sep 24, 2024David RisingerLeerink Partners$1.08K$1.09K-1.37%53.45%
Sep 24, 2024Brian SkorneyRobert W. Baird$940.00$1.09K-13.92%33.93%
Sep 24, 2024Salveen RichterGoldman Sachs$1.29K$1.09K18.32%84.08%
Sep 12, 2024Evan David SeigermanBMO Capital$1.30K$1.16K12.07%85.22%
Sep 09, 2024Brian AbrahamsRBC Capital$1.28K$1.14K12.51%82.66%
Aug 23, 2024Christopher RaymondRaymond James$1.24K$1.19K4.58%76.96%
Aug 02, 2024Geoff MeachamBank of America Securities$805.00$1.08K-25.29%14.70%
Aug 02, 2024Brian AbrahamsRBC Capital$1.24K$1.09K13.43%76.68%
Jul 19, 2024Christopher RaymondRaymond James$1.17K$1.06K9.63%66.13%
Jul 18, 2024Yatin SunejaGuggenheim$1.18K$1.09K8.69%68.13%
Jul 12, 2024Trung HuynhUBS$1.25K$1.09K14.44%78.10%
Jul 11, 2024Terence FlynnMorgan Stanley$1.18K$1.07K10.35%68.41%
Jun 25, 2024Jasper HellwegArgus Research$1.17K$1.06K9.97%66.70%
Jun 13, 2024Brian AbrahamsRBC Capital$1.30K$1.02K27.10%85.08%
Jun 12, 2024Brian AbrahamsRBC Capital$1.23K$1.01K21.62%75.11%
Jun 04, 2024Brian AbrahamsRBC Capital$1.20K$998.6420.16%70.98%
Jun 03, 2024Evan David SeigermanBMO Capital$1.08K$992.479.02%54.16%
May 20, 2024Christopher RaymondRaymond James$1.00K$982.291.80%42.48%
May 13, 2024Cory KasimovEvercore ISI$1.15K$976.9617.71%63.85%
May 03, 2024Brian AbrahamsRBC Capital$1.19K$937.6126.39%68.84%
Apr 12, 2024Akash TewariJefferies$1.06K$911.7816.26%51.03%
Apr 11, 2024Brian AbrahamsRBC Capital$1.19K$921.3429.05%69.41%
Mar 13, 2024Matthew HarrisonMorgan Stanley$1.11K$965.4715.49%58.87%
Jan 12, 2024Brian AbrahamsBMO Capital$1.08K$934.0515.20%53.31%
Jan 12, 2024Brian AbrahamsRBC Capital$1.08K$933.2015.30%53.31%
Mar 27, 2023Andrew BerensLeerink Partners$976.00$820.0019.02%39.06%
Mar 24, 2023Akash TewariJefferies$925.00$819.6812.85%31.79%
Feb 08, 2023EF Hutton$853.00$769.9410.79%21.54%
Feb 06, 2023RBC Capital$787.00$786.940.01%12.13%
Feb 06, 2023Morgan Stanley$883.00$783.1312.75%25.81%
Feb 06, 2023Leerink Partners$834.00$783.136.50%18.83%
Nov 11, 2022Guggenheim$915.00$707.6329.30%30.37%
Oct 03, 2022Goldman Sachs$970.00$726.9333.44%38.21%
Sep 16, 2022Canaccord Genuity$750.00$710.215.60%6.86%
Sep 13, 2022Piper Sandler$775.00$701.1510.53%10.42%
Sep 12, 2022Wells Fargo$800.00$718.8311.29%13.98%
Sep 09, 2022Barclays$815.00$708.8514.97%16.12%
Sep 09, 2022Matthew HarrisonMorgan Stanley$851.00$708.8520.05%21.25%
Sep 08, 2022Akash TewariJefferies$675.00$708.85-4.78%-3.83%
Aug 15, 2022Matthew HarrisonMorgan Stanley$625.00$628.71-0.59%-10.95%
Aug 04, 2022BMO Capital$788.00$614.9628.14%12.27%
Jul 15, 2022Morgan Stanley$619.00$604.302.43%-11.80%
Jun 29, 2022Kennen MacKayRBC Capital$638.00$597.626.76%-9.10%
Jun 11, 2022Mohit BansalWells Fargo$735.00$571.8128.54%4.72%
Jun 03, 2022Morgan Stanley$610.00$626.94-2.70%-13.09%
May 31, 2022Argus Research$760.00$683.0211.27%8.29%
May 23, 2022Geoffrey PorgesLeerink Partners$738.00$680.228.49%5.15%
May 23, 2022Lorenzo BiasioCredit Suisse$725.00$681.916.32%3.30%
May 05, 2022Morgan Stanley$620.00$638.13-2.84%-11.66%
Apr 16, 2022Carter GouldBarclays$745.00$733.021.63%6.15%
Feb 13, 2022Evan David SeigermanBMO Capital$780.00$638.4122.18%11.13%
Feb 07, 2022Carter GouldBarclays$700.00$622.3612.48%-0.26%
Feb 04, 2022Tyler Van BurenCowen & Co.$640.00$622.962.74%-8.81%
Feb 04, 2022Kennen MacKayRBC Capital$679.00$622.969.00%-3.26%
Feb 04, 2022Cory KasimovJ.P. Morgan$604.00$622.96-3.04%-13.94%
Feb 02, 2022Joshua SchimmerEvercore ISI$680.00$622.859.18%-3.11%
Jan 18, 2022Matthew HarrisonMorgan Stanley$585.00$611.22-4.29%-16.65%
Jan 03, 2022Aaron GalBernstein$660.00$627.105.25%-5.96%
Dec 06, 2021Salveen RichterGoldman Sachs$824.00$625.0031.84%17.40%
Nov 10, 2021Alethia YoungCantor Fitzgerald$760.00$622.2022.15%8.29%
Sep 09, 2021Esther RajaveluUBS$763.00$646.1118.09%8.71%
Jun 14, 2021Jasper HellwegArgus Research$590.00$528.7511.58%-15.94%
May 21, 2021John NewmanCanaccord Genuity$700.00$506.7238.14%-0.26%

The latest Regeneron Pharmaceuticals stock forecast, released on Nov 01, 2024 by Evan David Seigerman from BMO Capital, set a price target of $1.19K, which represents a 41.06% increase from the stock price at the time of the forecast ($843.60), and a 69.55% increase from REGN last price ($701.85).

Regeneron Pharmaceuticals Price Target by Period

1M3M12M
# Anlaysts-1032
Avg Price Target-$1.12K$1.15K
Last Closing Price$701.85$701.85$701.85
Upside/Downside-100.00%59.14%63.17%

In the current month, the average price target of Regeneron Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Regeneron Pharmaceuticals's last price of $701.85. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 13, 2024CitigroupNeutralInitialise
Nov 01, 2024Leerink PartnersMarket PerformMarket PerformHold
Oct 29, 2024Piper SandlerOverweightOverweightHold
Oct 24, 2024Evercore ISIOutperformOutperformHold
Oct 23, 2024SusquehannaNeutralNeutralHold
Oct 23, 2024Morgan StanleyOverweightOverweightHold
Oct 23, 2024OppenheimerOutperformOutperformHold
Oct 23, 2024BarclaysOverweightOverweightHold
Oct 23, 2024Cowen & Co.BuyBuyHold
Oct 23, 2024Wells FargoOverweightOverweightHold
Oct 04, 2024Wells FargoMarket PerformMarket PerformHold
Oct 04, 2024Truist FinancialUnderperformUnderperformHold
Sep 27, 2024Cowen & Co.BuyBuyHold
Sep 25, 2024Morgan StanleyOverweightOverweightHold
Sep 25, 2024Piper SandlerOverweightOverweightHold
Sep 24, 2024Leerink PartnersMarket PerformDowngrade
Sep 24, 2024Goldman SachsBuyBuyHold
Sep 12, 2024BMO CapitalOutperformOutperformHold
Sep 09, 2024RBC CapitalOutperformOutperformHold
Aug 26, 2024Cowen & Co.BuyBuyHold
Aug 23, 2024Wells FargoBuyBuyHold
Aug 23, 2024Sandler O'NeillUnderperformUnderperformHold
Aug 23, 2024Piper SandlerOverweightOverweightHold
Aug 02, 2024RBC CapitalBuyBuyHold
Aug 02, 2024Piper SandlerUnderperformUnderperformHold
Aug 02, 2024RBC CapitalOutperformOutperformHold
Aug 02, 2024BarclaysOverweightOverweightHold
Jul 19, 2024Piper SandlerOverweightOverweightHold
Jul 18, 2024GuggenheimBuyBuyHold
Jul 11, 2024UBSBuyBuyHold
Jul 11, 2024Morgan StanleyOverweightOverweightHold
Jul 10, 2024BarclaysOverweightOverweightHold
Jun 24, 2024RBC CapitalUnderperformUnderperformHold
Jun 14, 2024Cowen & Co.BuyBuyHold
Jun 12, 2024Wells FargoOverweightOverweightHold
Jun 04, 2024Truist FinancialUnderperformUnderperformHold
Jun 04, 2024UBSBuyBuyHold
Jun 04, 2024RBC CapitalOutperformOutperformHold
Jun 03, 2024BMO CapitalOutperformOutperformHold
May 20, 2024Piper SandlerOverweightOverweightHold
May 13, 2024Evercore ISIOutperformInitialise
May 03, 2024UBSBuyBuyHold
May 02, 2024RBC CapitalOutperformOutperformHold
Apr 12, 2024RBC CapitalUnderperformUnderperformHold
Apr 12, 2024Truist FinancialBuyBuyHold
Apr 12, 2024JefferiesBuyBuyHold
Apr 11, 2024RBC CapitalSector PerformSector PerformHold
Mar 26, 2024Morgan StanleyUnderperformUnderperformHold
Mar 26, 2024RBC CapitalBuyBuyHold
Mar 13, 2024Morgan StanleyOverweightOverweightHold
Feb 27, 2024Cowen & Co.UnderperformUnderperformHold
Feb 27, 2024RBC CapitalBuyBuyHold
Feb 06, 2024Cantor FitzgeraldNeutralNeutralHold
Jan 12, 2024RBC CapitalUnderperformOutperformUpgrade
Jan 09, 2024RBC CapitalUnderperformUnderperformHold
Jan 09, 2024Truist FinancialSector PerformSector PerformHold
Dec 18, 2023Truist FinancialSector PerformSector PerformHold
Dec 18, 2023RBC CapitalUnderperformUnderperformHold
Nov 03, 2023Raymond JamesMarket PerformOutperformUpgrade
Oct 16, 2023Cantor FitzgeraldNeutralNeutralHold
Jul 06, 2023Cantor FitzgeraldNeutralNeutralHold
Mar 31, 2023B. RileyOverweightOverweightHold
Mar 27, 2023SVB LeerinkMarket PerformOutperformUpgrade
Mar 24, 2023BMO CapitalOutperformOutperformHold
Mar 24, 2023JefferiesHoldBuyUpgrade
Mar 23, 2023Raymond JamesMarket PerformUpgrade
Feb 08, 2023EF HuttonBuyBuyHold
Feb 06, 2023RBC CapitalSector PerformSector PerformHold
Feb 06, 2023Morgan StanleyOverweightOverweightHold
Feb 06, 2023SVB LeerinkMarket PerformMarket PerformHold
Jan 30, 2023Cowen & Co.Market PerformOutperformUpgrade
Nov 11, 2022GuggenheimBuyBuyHold
Oct 03, 2022Goldman SachsBuyBuyHold
Sep 16, 2022Canaccord GenuityBuyBuyHold
Sep 12, 2022Piper SandlerOverweightOverweightHold
Sep 12, 2022Wells FargoOverweightOverweightHold
Sep 09, 2022BarclaysOverweightOverweightHold
Sep 09, 2022Morgan StanleyEqual-WeightOverweightUpgrade
Sep 08, 2022JefferiesHoldUpgrade
Sep 08, 2022BMO CapitalOutperformOutperformHold
Aug 04, 2022BMO CapitalOutperformOutperformHold
Jul 30, 2022Cowen & Co.Market PerformMarket PerformHold
Jul 15, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Jun 29, 2022RBC CapitalSector PerformSector PerformHold
Jun 10, 2022Piper SandlerOverweightOverweightHold
Jun 03, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Jun 03, 2022Wells FargoOverweightOverweightHold
May 31, 2022Argus ResearchBuyBuyHold
May 23, 2022Credit SuisseBuyBuyHold
May 02, 2022RBC CapitalSector PerformSector PerformHold
Apr 25, 2022Cowen & Co.Market PerformMarket PerformHold
Apr 15, 2022BarclaysOverweightOverweightHold
Feb 26, 2022Piper SandlerOverweightOverweightHold
Feb 13, 2022BMO CapitalOutperformOutperformHold
Feb 07, 2022BarclaysOverweightOverweightHold
Jan 03, 2022BernsteinOutperformUpgrade
Dec 06, 2021Goldman SachsBuyInitialise
Aug 23, 2021BenchmarkBuyBuyHold
Aug 07, 2021OppenheimerOutperformOutperformHold

Regeneron Pharmaceuticals's last stock rating was published by Citigroup on Nov 13, 2024. The company Initialise its REGN rating from "null" to "Neutral".

Regeneron Pharmaceuticals Financial Forecast

Regeneron Pharmaceuticals Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
Revenue--------$3.43B$3.36B$3.16B$3.16B$3.41B$2.94B$2.86B$2.97B$4.95B$3.45B$5.14B$2.53B$2.42B$2.29B$1.95B$1.83B$2.17B$2.05B$1.93B$1.71B$1.51B$1.32B
Avg Forecast$3.99B$3.89B$3.79B$3.56B$3.76B$3.67B$3.38B$3.23B$3.29B$3.23B$3.02B$3.00B$3.12B$2.92B$2.79B$2.69B$4.56B$2.75B$3.96B$2.50B$2.42B$2.08B$1.73B$1.76B$2.11B$1.99B$1.80B$1.77B$1.41B$1.38B
High Forecast$4.30B$4.19B$4.09B$3.75B$4.11B$3.68B$3.38B$3.23B$3.43B$3.38B$3.26B$3.23B$3.37B$2.92B$2.79B$2.69B$4.56B$2.75B$3.96B$2.50B$2.42B$2.08B$1.73B$1.76B$2.11B$1.99B$1.80B$1.77B$1.69B$1.66B
Low Forecast$3.72B$3.63B$3.54B$3.42B$3.59B$3.67B$3.38B$3.23B$2.99B$3.01B$2.82B$2.80B$2.91B$2.92B$2.79B$2.69B$4.56B$2.75B$3.96B$2.50B$2.42B$2.08B$1.73B$1.76B$2.11B$1.99B$1.80B$1.77B$1.13B$1.11B
# Analysts11141685482010109999101010101099913131313157
Surprise %--------1.04%1.04%1.04%1.05%1.09%1.01%1.02%1.10%1.09%1.26%1.30%1.01%1.00%1.10%1.13%1.04%1.03%1.03%1.07%0.97%1.07%0.95%

Regeneron Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 4 analysts is $3.23B, with a low forecast of $3.23B, and a high forecast of $3.23B. REGN's average Quarter revenue forecast represents a -6.09% decrease compared to the company's last Quarter revenue of $3.43B (Dec 23).

Regeneron Pharmaceuticals EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11141685482010109999101010101099913131313157
EBITDA--------$972.90M$1.11B$1.02B$1.03B$1.37B$1.62B$1.17B$1.18B$2.59B$1.90B$3.84B$1.33B$1.30B$1.08B$987.40M$730.80M$950.80M$829.20M$284.80M$604.80M$628.20M$477.90M
Avg Forecast$1.71B$1.67B$1.62B$1.53B$1.61B$1.57B$1.45B$1.17B$1.41B$1.38B$1.29B$1.06B$2.39B$1.25B$1.19B$963.12M$1.95B$1.17B$1.69B$1.20B$1.03B$889.44M$737.33M$674.77M$899.97M$848.52M$770.55M$717.58M$581.98M$499.77M
High Forecast$1.84B$1.80B$1.75B$1.60B$1.76B$1.58B$1.45B$1.40B$1.47B$1.45B$1.39B$1.27B$2.87B$1.25B$1.19B$1.16B$1.95B$1.17B$1.69B$1.44B$1.03B$889.44M$737.33M$809.72M$899.97M$848.52M$770.55M$861.09M$698.38M$599.72M
Low Forecast$1.59B$1.55B$1.51B$1.47B$1.53B$1.57B$1.45B$932.30M$1.28B$1.29B$1.21B$847.54M$1.91B$1.25B$1.19B$770.49M$1.95B$1.17B$1.69B$962.39M$1.03B$889.44M$737.33M$539.81M$899.97M$848.52M$770.55M$574.06M$465.59M$399.82M
Surprise %--------0.69%0.80%0.79%0.97%0.57%1.30%0.98%1.22%1.33%1.62%2.27%1.11%1.26%1.22%1.34%1.08%1.06%0.98%0.37%0.84%1.08%0.96%

4 analysts predict REGN's average Quarter EBITDA for Mar 24 to be $1.17B, with a high of $1.40B and a low of $932.30M. This is 19.78% upper than Regeneron Pharmaceuticals's previous annual EBITDA (Dec 23) of $972.90M.

Regeneron Pharmaceuticals Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11141685482010109999101010101099913131313157
Net Income--------$1.16B$1.01B$968.40M$817.80M$1.20B$1.32B$852.10M$973.50M$2.23B$1.63B$3.10B$1.12B$1.15B$842.10M$897.30M$624.60M$792.00M$669.60M$193.10M$461.10M$477.98M$248.93M
Avg Forecast$1.38B$1.53B$1.47B$1.27B$1.31B$1.36B$1.23B$987.37M$1.25B$1.24B$1.14B$897.61M$2.06B$1.13B$994.55M$816.01M$2.35B$1.19B$2.05B$1.00B$966.97M$802.38M$682.36M$576.71M$799.77M$738.72M$625.97M$547.08M$442.82M$260.32M
High Forecast$1.51B$1.68B$1.61B$1.38B$1.53B$1.37B$1.23B$1.18B$1.41B$1.39B$1.26B$1.08B$2.47B$1.13B$994.55M$979.21M$2.35B$1.19B$2.05B$1.21B$966.97M$802.38M$682.36M$692.05M$799.77M$738.72M$625.97M$656.50M$531.38M$312.38M
Low Forecast$1.26B$1.39B$1.34B$1.15B$1.19B$1.35B$1.23B$789.90M$900.22M$991.15M$1.04B$718.09M$1.64B$1.13B$994.55M$652.81M$2.35B$1.19B$2.05B$803.94M$966.97M$802.38M$682.36M$461.37M$799.77M$738.72M$625.97M$437.67M$354.25M$208.26M
Surprise %--------0.93%0.81%0.85%0.91%0.58%1.17%0.86%1.19%0.95%1.37%1.52%1.11%1.19%1.05%1.31%1.08%0.99%0.91%0.31%0.84%1.08%0.96%

Regeneron Pharmaceuticals's average Quarter net income forecast for Mar 24 is $987.37M, with a range of $789.90M to $1.18B. REGN's average Quarter net income forecast represents a -14.85% decrease compared to the company's last Quarter net income of $1.16B (Dec 23).

Regeneron Pharmaceuticals SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11141685482010109999101010101099913131313157
SG&A--------$737.70M$640.50M$652.00M$601.10M$660.50M$529.10M$476.30M$450.00M$559.60M$445.00M$414.70M$405.60M$303.50M$326.90M$348.30M$367.30M$586.80M$419.90M$417.30M$410.80M$330.77M$296.85M
Avg Forecast$702.35M$684.97M$667.69M$627.22M$662.24M$646.55M$595.30M$456.41M$579.61M$568.67M$531.89M$414.92M$515.93M$512.93M$491.65M$377.20M$802.74M$483.18M$697.29M$365.49M$425.34M$366.30M$303.66M$339.14M$370.64M$349.45M$317.34M$487.40M$306.44M$310.43M
High Forecast$756.67M$737.94M$719.32M$659.39M$723.39M$647.90M$595.30M$547.69M$602.73M$594.27M$573.02M$497.90M$619.12M$512.93M$491.65M$452.64M$802.74M$483.18M$697.29M$438.59M$425.34M$366.30M$303.66M$406.97M$370.64M$349.45M$317.34M$584.88M$367.72M$372.51M
Low Forecast$654.79M$638.59M$622.48M$602.20M$630.79M$645.20M$595.30M$365.13M$526.28M$529.07M$495.87M$331.94M$412.74M$512.93M$491.65M$301.76M$802.74M$483.18M$697.29M$292.39M$425.34M$366.30M$303.66M$271.31M$370.64M$349.45M$317.34M$389.92M$245.15M$248.34M
Surprise %--------1.27%1.13%1.23%1.45%1.28%1.03%0.97%1.19%0.70%0.92%0.59%1.11%0.71%0.89%1.15%1.08%1.58%1.20%1.31%0.84%1.08%0.96%

Regeneron Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $456.41M, based on 4 Wall Street analysts, with a range of $365.13M to $547.69M. The forecast indicates a -38.13% fall compared to REGN last annual SG&A of $737.70M (Dec 23).

Regeneron Pharmaceuticals EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11141685482010109999101010101099913131313157
EPS--------$10.88$9.48$9.05$7.64$11.19$12.31$7.90$9.12$20.99$15.37$29.51$10.58$10.90$7.98$8.19$5.69$7.25$6.12$1.77$4.23$4.44$2.36
Avg Forecast$11.84$13.16$12.62$10.89$11.27$11.69$10.62$10.17$10.73$10.68$9.85$9.52$10.25$9.76$8.62$9.72$20.40$10.35$17.72$8.68$8.38$6.95$5.91$6.06$6.93$6.40$5.42$5.48$4.03$3.20
High Forecast$13.03$14.48$13.89$11.88$13.16$11.77$10.62$10.17$12.12$11.95$10.84$10.48$11.28$9.76$8.62$9.72$20.40$10.35$17.72$8.68$8.38$6.95$5.91$6.06$6.93$6.40$5.42$5.48$4.84$3.84
Low Forecast$10.80$12.00$11.51$9.89$10.27$11.61$10.62$10.17$7.75$8.53$8.98$8.68$9.35$9.76$8.62$9.72$20.40$10.35$17.72$8.68$8.38$6.95$5.91$6.06$6.93$6.40$5.42$5.48$3.22$2.56
Surprise %--------1.01%0.89%0.92%0.80%1.09%1.26%0.92%0.94%1.03%1.49%1.67%1.22%1.30%1.15%1.39%0.94%1.05%0.96%0.33%0.77%1.10%0.74%

According to 4 Wall Street analysts, Regeneron Pharmaceuticals's projected average Quarter EPS for Mar 24 is $10.17, with a low estimate of $10.17 and a high estimate of $10.17. This represents a -6.52% decrease compared to REGN previous annual EPS of $10.88 (Dec 23).

Regeneron Pharmaceuticals Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
NTLAIntellia Therapeutics$13.13$53.00303.66%Buy
APLSApellis Pharmaceuticals$34.53$70.80105.04%Buy
RAREUltragenyx Pharmaceutical$44.95$90.00100.22%Buy
CRSPCRISPR Therapeutics$44.63$77.5073.65%Buy
IONSIonis Pharmaceuticals$37.68$58.3354.80%Buy
REGNRegeneron Pharmaceuticals$740.01$1.14K53.40%Buy
BGNEBeiGene$179.06$267.3349.30%Buy
SRPTSarepta Therapeutics$125.76$187.2048.85%Buy
NVONovo Nordisk$108.01$158.0046.28%Buy
BMRNBioMarin Pharmaceutical$67.19$94.4340.54%Buy
INCYIncyte$69.40$90.1129.84%Buy
ALNYAlnylam Pharmaceuticals$246.58$310.6025.96%Buy
ARWRArrowhead Pharmaceuticals$22.27$27.7424.56%Buy
KRYSKrystal Biotech$169.04$210.3324.43%Buy
UTHRUnited Therapeutics$379.69$440.4015.99%Buy
MDGLMadrigal Pharmaceuticals$306.08$315.753.16%Buy
PTCTPTC Therapeutics$47.02$48.002.08%Hold

REGN Forecast FAQ

Is Regeneron Pharmaceuticals a good buy?

Yes, according to 26 Wall Street analysts, Regeneron Pharmaceuticals (REGN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 22 'Buy' recommendations, accounting for 84.62% of REGN's total ratings.

What is REGN's price target?

Regeneron Pharmaceuticals (REGN) average price target is $1.14K with a range of $805 to $1.29K, implying a 61.74% from its last price of $701.85. The data is based on 26 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Regeneron Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for REGN stock, the company can go up by 61.74% (from the last price of $701.85 to the average price target of $1.14K), up by 84.08% based on the highest stock price target, and up by 14.70% based on the lowest stock price target.

Can Regeneron Pharmaceuticals stock reach $1.1K?

REGN's average twelve months analyst stock price target of $1.14K supports the claim that Regeneron Pharmaceuticals can reach $1.1K in the near future.

What are Regeneron Pharmaceuticals's analysts' financial forecasts?

Regeneron Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $14.05B (high $14.4B, low $13.86B), average EBITDA is $5.8B (high $6.18B, low $5.49B), average net income is $4.89B (high $5.32B, low $4.57B), average SG&A $2.36B (high $2.51B, low $2.24B), and average EPS is $43.76 (high $45.72, low $42.67). REGN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $15.25B (high $16.33B, low $14.31B), average EBITDA is $6.53B (high $6.99B, low $6.13B), average net income is $5.64B (high $6.19B, low $5.14B), average SG&A $2.68B (high $2.87B, low $2.52B), and average EPS is $48.51 (high $53.28, low $44.2).

Did the REGN's actual financial results beat the analysts' financial forecasts?

Based on Regeneron Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $13.12B, beating the average analysts forecast of $12.55B by 4.53%. Apple's EBITDA was $4.05B, missing the average prediction of $5.15B by -21.38%. The company's net income was $3.95B, missing the average estimation of $4.53B by -12.72%. Apple's SG&A was $2.63B, beating the average forecast of $2.1B by 25.59%. Lastly, the company's EPS was $37.05, missing the average prediction of $40.78 by -9.15%. In terms of the last quarterly report (Dec 2023), Regeneron Pharmaceuticals's revenue was $3.43B, beating the average analysts' forecast of $3.29B by 4.25%. The company's EBITDA was $972.9M, missing the average prediction of $1.41B by -31.01%. Regeneron Pharmaceuticals's net income was $1.16B, missing the average estimation of $1.25B by -7.00%. The company's SG&A was $737.7M, beating the average forecast of $579.61M by 27.27%. Lastly, the company's EPS was $10.88, beating the average prediction of $10.73 by 1.39%